Kernalbio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $25M

  • Investors
  • 45

Kernalbio General Information

Description

Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. The company's platform decreases immunogenicity upon existing mRNA technologies and enables cell-specific therapeutic protein expression, enabling clinicians with more efficacious, tolerable, and affordable medicine for the global market.

Contact Information

Website
www.kernalbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 238 Main Street
  • Cambridge, MA 02142
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 238 Main Street
  • Cambridge, MA 02142
  • United States
+1 (857)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kernalbio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 07-Jul-2022 $25M Completed Generating Revenue
5. Later Stage VC (Series 2) 04-Feb-2021 Completed Pre-Clinical Trials
4. Seed Round 21-Oct-2020 Completed Pre-Clinical Trials
3. Accelerator/Incubator 26-Aug-2020 Completed Pre-Clinical Trials
2. Accelerator/Incubator 18-Oct-2018 $500K $1.35M Completed Pre-Clinical Trials
1. Angel (individual) 14-Aug-2018 $850K $850K Completed Pre-Clinical Trials
To view Kernalbio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Kernalbio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. The company's platfor
Drug Discovery
Cambridge, MA
15 As of 2025

Emeryville, CA
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kernalbio Competitors (3)

One of Kernalbio’s 3 competitors is Nutcracker Therapeutics, a Venture Capital-Backed company based in Emeryville, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nutcracker Therapeutics Venture Capital-Backed Emeryville, CA
Sirnaomics Formerly VC-backed Gaithersburg, MD
TransCode Therapeutics Formerly VC-backed Newton, MA
You’re viewing 3 of 3 competitors. Get the full list »

Kernalbio Patents

  • 15

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 15

    Pending

  • Expiring in next 12 mo

Kernalbio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4429645-A1 Oncoselective cancer therapy Pending 08-Nov-2021
US-20240358797-A1 Oncoselective cancer therapy Pending 08-Nov-2021
EP-4415690-A1 Compositions and methods for delivery of agents Pending 14-Oct-2021
US-20240067684-A1 Constitutively active payloads Pending 23-Dec-2020
AU-2020297594-A1 Engineered oncoselective protein expression Pending 21-Jun-2019 C12N15/11
To view Kernalbio’s complete patent history, request access »

Kernalbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kernalbio Investors (45)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amgen Ventures Corporate Venture Capital Minority
Amino Collective Venture Capital Minority
BlueLotus Ventures Venture Capital Minority
Expanding Capital Venture Capital Minority
HBM Genomics Venture Capital Minority
You’re viewing 5 of 45 investors. Get the full list »

Ready to get started?

Request a free trial

Kernalbio FAQs

  • When was Kernalbio founded?

    Kernalbio was founded in 2016.

  • Where is Kernalbio headquartered?

    Kernalbio is headquartered in Cambridge, MA.

  • What is the size of Kernalbio?

    Kernalbio has 15 total employees.

  • What industry is Kernalbio in?

    Kernalbio’s primary industry is Drug Discovery.

  • Is Kernalbio a private or public company?

    Kernalbio is a Private company.

  • What is Kernalbio’s current revenue?

    The current revenue for Kernalbio is .

  • How much funding has Kernalbio raised over time?

    Kernalbio has raised $37M.

  • Who are Kernalbio’s investors?

    Amgen Ventures, Amino Collective, BlueLotus Ventures, Expanding Capital, and HBM Genomics are 5 of 45 investors who have invested in Kernalbio.

  • Who are Kernalbio’s competitors?

    Nutcracker Therapeutics, Sirnaomics, and TransCode Therapeutics are competitors of Kernalbio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »